Cvs Chest Congestion Relief

Description

The SPL Code for this product is 34089-3. Further details regarding the chemical composition, structural formula, inactive ingredients, and other specific characteristics are currently not provided.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with minor throat and bronchial irritation, which may occur due to a common cold. It aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating the clearance of bothersome mucus from the bronchial passageways. Additionally, this medication helps to make coughs more productive.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children 12 years of age and over are instructed to take 1 tablet every 4 hours as needed. For children aged 6 to under 12 years, the recommended dosage is 1/2 tablet every 4 hours as needed. It is important to note that for children under 6 years of age, consultation with a doctor is required prior to administration.

Healthcare professionals should advise patients not to exceed 6 doses within a 24-hour period, unless otherwise directed by a physician.

Contraindications

Use of this product is contraindicated in the following situations:

• Patients currently taking a prescription monoamine oxidase inhibitor (MAOI) due to the risk of serious interactions.

• Patients using certain medications for depression, psychiatric or emotional conditions, or Parkinson's disease, as these may lead to adverse effects.

• Patients who have discontinued MAOI therapy within the past two weeks, as residual effects may still pose a risk.

Warnings and Precautions

The use of this product is contraindicated in individuals currently taking a prescription monoamine oxidase inhibitor (MAOI) or within two weeks of discontinuing an MAOI. Healthcare professionals should advise patients to consult their doctor or pharmacist if they are uncertain whether their prescription medication contains an MAOI prior to using this product.

Patients should be cautioned to seek medical advice before using this product if they have a persistent or chronic cough, particularly those associated with smoking, asthma, bronchitis, or emphysema. Additionally, individuals experiencing a cough accompanied by excessive phlegm (mucous) should also consult their healthcare provider.

In the event of an overdose, it is imperative to seek emergency medical assistance or contact a Poison Center immediately.

Patients are advised to discontinue use and consult their doctor if they experience any of the following: symptoms accompanied by fever, rash, or a persistent headache; a cough that persists for more than one week or tends to recur; or if a persistent cough is suspected to indicate a serious underlying condition.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious adverse reactions may occur, particularly in patients who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or have taken one within the past two weeks. The use of this medication in such cases is contraindicated.

Common adverse reactions may include symptoms that warrant immediate medical attention. Patients are advised to stop use and consult a healthcare professional if symptoms are accompanied by fever, rash, or a persistent headache. Additionally, if a cough persists for more than one week or tends to recur, it may indicate a serious underlying condition, and medical advice should be sought.

Before initiating treatment, patients should consult their healthcare provider if they have a persistent or chronic cough, such as that associated with smoking, asthma, bronchitis, or emphysema. Furthermore, if the cough is accompanied by excessive phlegm (mucous), it is important to seek medical advice prior to use.

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not use this product if they are currently taking an MAOI or certain medications prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, it is advised to avoid this product for a period of two weeks following the discontinuation of an MAOI.

Patients are encouraged to consult with their healthcare provider or pharmacist to confirm whether their current prescription includes an MAOI before initiating treatment with this product.

Packaging & NDC

Below are the non-prescription pack sizes of Cvs Chest Congestion Relief (dextromethorphan hydrobromide / guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may take 1/2 tablet every 4 hours as needed, with a maximum of 6 doses in a 24-hour period or as directed by a healthcare provider. For children under 6 years of age, consultation with a doctor is required prior to use.

It is important to keep the medication out of reach of children. In the event of an overdose, immediate medical assistance or contact with a Poison Center is necessary.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits, as well as any available data regarding fetal outcomes and breastfeeding safety. Healthcare providers should consider individual circumstances and the specific health needs of the patient when making recommendations.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be considered as part of standard clinical practice.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

If available, specific antidotes or treatments should be administered as indicated based on the clinical scenario and the substance involved. Consultation with a poison control center or a medical toxicologist may be beneficial for guidance on management strategies tailored to the specific situation.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children. In the event of an overdose, patients should seek medical help or contact a Poison Center immediately.

Patients should be informed not to use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or certain medications for depression, psychiatric or emotional conditions, or Parkinson's disease. They should also refrain from using this product for at least two weeks after discontinuing an MAOI. If patients are uncertain whether their prescription medication contains an MAOI, they should consult their doctor or pharmacist prior to using this product.

Healthcare providers should instruct patients to stop using the medication and consult their doctor if symptoms are accompanied by fever, rash, or a persistent headache. Additionally, if a cough persists for more than one week or tends to recur, patients should be advised to seek medical attention, as a persistent cough may indicate a serious condition.

It is also important for healthcare providers to recommend that patients ask their doctor before using this product if they have a persistent or chronic cough, such as that associated with smoking, asthma, bronchitis, or emphysema, or if their cough is accompanied by excessive phlegm (mucous).

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It is crucial to store the product at a temperature range of 15°C to 30°C (59°F to 86°F) to maintain its efficacy and safety.

To ensure proper handling, the product should be kept out of reach of children. Additionally, it is important to discard the product after opening to prevent any potential contamination or degradation.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. It is important to keep the medication out of reach of children, and in the event of an overdose, patients should seek medical assistance or contact a Poison Center immediately.

Drug Information (PDF)

This file contains official product information for Cvs Chest Congestion Relief, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)